Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Company Drug

FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment

Fineline Cube Nov 30, 2022

US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...

Company

Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park

Fineline Cube Nov 30, 2022

Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...

Company Drug

Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment

Fineline Cube Nov 29, 2022

China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...

R&D

Hong Kong Researchers Identify New Target for Epilepsy Treatment

Fineline Cube Nov 29, 2022

Researchers at the University of Hong Kong have published the results of a study that...

Company Drug

Hope Medicine Gains Global Approval for Phase II Trial of HMI-115

Fineline Cube Nov 29, 2022

China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Policy / Regulatory

NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports

Fineline Cube Nov 29, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...

Company Deals

I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies

Fineline Cube Nov 29, 2022

China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...

Company Deals

Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round

Fineline Cube Nov 29, 2022

China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...

Company

Alibaba Health Reports 22.9% Revenue Growth in H1 2022

Fineline Cube Nov 29, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...

Company Deals

3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million

Fineline Cube Nov 29, 2022

China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...

Company Policy / Regulatory

China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact

Fineline Cube Nov 28, 2022

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau

Fineline Cube Nov 28, 2022

China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...

Deals

Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement

Fineline Cube Nov 28, 2022

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...

Company Drug

Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC

Fineline Cube Nov 28, 2022

Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...

Company Deals

ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round

Fineline Cube Nov 28, 2022

China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...

Company

Ascentage Pharma Receives Drug Production License for Suzhou Plant

Fineline Cube Nov 28, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...

Company Drug

Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea

Fineline Cube Nov 28, 2022

China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...

Company

Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo

Fineline Cube Nov 28, 2022

The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...

Company Deals

Huadong Medicine Partners with Dongyang Med for Equity Collaboration

Fineline Cube Nov 28, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...

Posts pagination

1 … 556 557 558 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.